top of page
The Professional Network for Healthcare Experts
Slate Medicines to merge with Fulcrum Therapeutics and raise $245 million to advance migraine pipeline
The reverse-merger transaction gives privately held Slate a Nasdaq listing and additional capital to advance its anti-PACAP migraine portfolio, led by clinical-stage monoclonal antibody SLTE-1009.
nuaxia
Aug 193 min read
Vedana launches with $46M to chase the next wave of migraine innovation beyond CGRP therapies
A new biotech focused exclusively on migraine treatment has emerged with significant financial backing and a leadership team responsible for some of the most important advances in migraine medicine over the last decade.
nuaxia
Jun 203 min read
bottom of page